Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
NCT ID | NCT03914300 |
Title | Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer |
Recruitment | Suspended |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | National Cancer Institute (NCI) |
Indications |
thyroid gland papillary carcinoma |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |